From Yahoo Finance: 2025-06-17 13:35:00

NeuroPace, Inc. (NASDAQ:NPCE) is one of the best NASDAQ stocks under $50 to buy, with Cantor Fitzgerald reaffirming an Overweight rating and $16.00 price target, representing a 44% upside. The company’s RNS System for epilepsy garnered positive feedback from a survey of 30 medical professionals.

With a one-year return outpacing the market by 60.82%, NeuroPace, Inc. (NASDAQ:NPCE) is on a positive trajectory. The company specializes in responsive neurostimulation technology for detecting seizure-related brain activity patterns. Its RNS System is approved for specific epilepsy types, with potential for use in idiopathic generalized epilepsy (IGE).

Founded in 1997, NeuroPace, Inc. (NASDAQ:NPCE) is a U.S.-based medical device company focused on developing RNS systems to improve the lives of epilepsy patients. The company also offers physician tablets and patient data management systems as part of its services.

While NeuroPace (NPCE) shows promise as an investment, other AI stocks may offer greater upside potential with lower downside risk. A free report on the best short-term AI stock could be a valuable resource for investors seeking undervalued opportunities in the current market.

Read more: NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey